Innate Pharma SA: Monalizumab data from NeoCOAST-2 Phase 2 study in early-stage NSCLC presented at WCLC 2024 Page 1

Regulatory News:

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN) presented interim results from the randomized NeoCOAST-2 (NCT05061550) Phase 2 platform study at the World Conference on Lung Cancer 2024 on September 8, 2024.

The NeoCOAST-2 platform trial is designed to evaluate the safety and efficacy of neoadjuvant durvalumab alone or combined with novel agents and chemotherapy in resectable, early-stage non-small cell lung cancer (NSCLC), followed by adjuvant treatment with durvalumab with or without the novel agents. Preliminary data from three arms were presented at WCLC, namely: